Skip to main content Skip to accessibility
This website is not compatible with your web browser. You should install a newer browser. If you live in Jersey and need help upgrading call the States of Jersey web team on 440099.
Government of Jerseygov.je

Information and public services for the Island of Jersey

L'înformâtion et les sèrvices publyis pouor I'Île dé Jèrri

Prescribed List (Jersey): Changes as of 1 September 2020

A formal published “Ministerial Decision” is required as a record of the decision of a Minister (or an Assistant Minister where they have delegated authority) as they exercise their responsibilities and powers.

Ministers are elected by the States Assembly and have legal responsibilities and powers as “corporation sole” under the States of Jersey Law 2005 by virtue of their office and in their areas of responsibility, including entering into agreements, and under any legislation conferring on them powers.

An accurate record of “Ministerial Decisions” is vital to effective governance, including:

  • demonstrating that good governance, and clear lines of accountability and authority, are in place around decisions-making – including the reasons and basis on which a decision is made, and the action required to implement a decision

  • providing a record of decisions and actions that will be available for examination by States Members, and Panels and Committees of the States Assembly; the public, organisations, and the media; and as a historical record and point of reference for the conduct of public affairs

Ministers are individually accountable to the States Assembly, including for the actions of the departments and agencies which discharge their responsibilities.

The Freedom of Information Law (Jersey) Law 2011 is used as a guide when determining what information is be published. While there is a presumption toward publication to support of transparency and accountability, detailed information may not be published if, for example, it would constitute a breach of data protection, or disclosure would prejudice commercial interest.

A decision made on 18 August 2020

Decision Reference:  MD-S-2020-0051

Decision Summary Title :

DS Prescribed list as of 1 September 2020

Date of Decision Summary:

29 July 2020

Decision Summary Author:

Policy Principal

Decision Summary:

Public or Exempt?

Public

Type of Report:

Oral or Written?

Written

Person Giving

Oral Report:

NA

Written Report

Title :

WR report PBAC 14 July 2020

Date of Written Report:

29 July 2020

Written Report Author:

Prescribing Advisor

Written Report :

Public or Exempt?

 

Public

Subject: Changes to be made to the Prescribed List (Jersey) as of 1 September 2020

Decision(s): Further to Article 15, paragraphs (11) and (12), of the Health Insurance (Jersey) Law 1967, and having consulted with the Pharmaceutical Benefit Advisory Committee, the Minister decided to make amendments to the Prescribed List with effect from 1 September 2020 as set out in the accompanying report and supporting document.

Reason(s) for Decision: The Pharmaceutical Benefit Advisory Committee met to consider applications for changes to the Prescribed List and made the following recommendations-

1.      Items to be added to the Prescribed List

 

1.1 Vortioxetine 5mg, 10mg, 15mg tablet

1.2 Esomeprazole 20mg, 40mg gastro-resistant capsule

1.3 Estradiol 1.53mg/dose transdermal spray (Lenzetto)

1.4 Synalar N ointment

1.5 Medroxyprogesterone 100mg tablet

1.6 Isosorbide mononitrate 60mg m/r tablet

1.7 Methotrexate 22.5mg and 30mg solution for injection pre-filled device

1.8  Budesonide 9mg m/r tablet

 

  1. Items to be removed from the Prescribed List

 

2.1  Furosemide 5mg/5ml oral solution

2.2  Ketoprofen 50mg capsules

2.3  Spironolactone 10mg/5mL oral suspension

 

  1. Other changes to the Prescribed List

 

3.1   The requirement for prescriptions for acamprosate and nalmefene to be validated by the Alcohol & Drugs Service before dispensing is suspended during the COVID-19 pandemic pending review of the process.

 

The above recommendations reflect current evidence and expert advice and ensure that patients in Jersey have access to an appropriate range of modern, safe and effective treatments from their GPs and community prescribers at a proportionate cost to the Fund.

 

Resource Implications: The overall financial impact of the above changes is expected to be a small cost pressure of up to £10,000 per annum.  

 

Action required: Health Zone Manager at Customer and Local Services to issue a public notice listing amendments and notify all approved medical practitioners and approved contractors.

Signature:

 

 

Position:

Minister for Social Security

 

Date Signed:

 

 

Date of Decision (If different from Date Signed):

 

Hide report
Prescribed List (Jersey): Changes as of 1 September 2020

RECOMMENDATIONS OF THE

PHARMACEUTICAL BENEFIT ADVISORY COMMITTEE

 

Summary

 

The Pharmaceutical Benefit Advisory Committee (PBAC) met on 14 July 2020 to consider applications for changes to the Prescribed List.

The PBAC was unanimous in its recommendations for the following changes to the Prescribed List to be implemented from 1 September 2020, unless stated otherwise.

 

1.      Items to be added to the Prescribed List

 

1.1 Vortioxetine tablets 5mg, 10mg, 15mg

1.2 Esomeprazole gastro-resistant capsule 20mg, 40mg

1.3 Estradiol 1.53mg/dose transdermal spray (Lenzetto)

1.4 Synalar N ointment

1.5 Medroxyprogesterone 100mg tablets

1.6 Isosorbide mononitrate MR 60mg Tablets

1.7 Methotrexate injection 22.5mg and 30mg

1.8 Budesonide m/r tablet 9mg

 

2.      Items to be removed from the Prescribed List

 

2.1  Furosemide 5mg/5ml oral solution

2.2   Ketoprofen 50mg capsules

2.3   Spironolactone 10mg/5mL oral suspension

1

 


 


 

  1. Other changes to the Prescribed List

 

3.1 The requirement for prescriptions for acamprosate and nalmefene to be validated by the Alcohol & Drugs Service before dispensing is suspended during the COVID-19 pandemic pending review of the process.

 

  1. Other considerations

 

Applications for the following products were considered by the Committee but not supported.

4.1 Hyaluronic acid injection (e.g. Ostenil Plus, Durolane)

4.2 Colecalciferol (vitamin D) capsules 400 Units, 800units

 

Financial impact

 

The overall financial impact of the above changes is expected to be an increase in expenditure of up to `£10,000 pa.  

 

Mrs Alison Creed, PBAC Chair

20 July 2020

 

Recommendations

 

  1. Items to be added to the Prescribed List

 

1.1  Vortioxetine tablets 5mg, 10mg, 15mg

 

Vortioxetine is an antidepressant licensed for the treatment of major depression in adults. It is supported by NICE “as an option for treating major depressive episodes in adults whose condition has responded inadequately to 2 antidepressants within the current episode.” Local psychiatrists find it particularly helpful in those who experience unwanted sexual side-effects with existing antidepressant options. The Committee recommend the addition of vortioxetine for prescribing in primary care only in patients who have been initiated by a hospital specialist.

 

1.2  Esomeprazole gastro-resistant capsule 20mg, 40mg

 

Esomeprazole is a proton pump inhibitor (PPI) that reduces the production of acid in the stomach and is used for the treatment of dyspepsia and other acid-related disorders. There are three other PPIs included in the Prescribed List. All four PPIs are now available as lower price generic products; esomeprazole is slightly more expensive than the others (£30-£50 pa compared with £15-£40pa). Esomeprazole is used in hospital practice, partly because patients will often have tried other PPIs before referral, but, in some patients, esomeprazole is found to be more effective. The Committee recommended the addition of esomeprazole to provide an alternative PPI and facilitate prescribing in the community for patients currently receiving repeat prescriptions through the hospital.

 

1.3  Estradiol 1.53mg/dose transdermal spray (Lenzetto)

 

Estradiol is used as hormone replacement therapy for the management of estrogen deficiency symptoms in postmenopausal women. It is commonly administered through the skin as a safer route than oral administration. Estadiol patches and estradiol gels are included in the Prescribed List but use of each of these forms can be problematic. The transdermal spray provides an alternative method of administration that can offer a few practical advantages, for example avoiding the adhesives used on patches that can cause skin reactions, and being less messy than gels. At usual daily doses, the transdermal spray has a similar cost to other transdermal products. The Committee recommended the addition of estradiol transdermal spray as an alternative to other transdermal estradiol products.

 

 

The Committee recommended addition of the following items, which provide alternative formulations or additional strengths for products already included in the Prescribed List, with no cost impact.

 

1.4  Synalar N ointment – as an alternative to Synalar N cream

 

1.5  Medroxyprogesterone 100mg tablets – to add to 5mg, 10mg and 200mg strengths included in Prescribed List

 

1.6 Isosorbide mononitrate MR 60mg Tablets - as alternative to capsules included in the Prescribed List

 

1.7  Methotrexate injection 22.5mg and 30mg - to add to all other strengths included in Prescribed List

 

1.8  Budesonide m/r tablet 9mg – as a once daily alternative to budesonide 3mg m/r capsule, which is taken 3-times daily.

 

2.      Items to be removed from the Prescribed List

 

2.1 Furosemide 5mg/5ml oral solution – this product is now discontinued

2.2  Ketoprofen 50mg capsules – this product is now discontinued

2.3  Spirololactone 10mg/5mL oral suspension – in  accordance with  UK guidance,  the range  of liquid products for children should be rationalised to standard strengths; the 10mg/5mL oral suspension is recommended for removal while the 50mg/5mL oral suspension will remain on the  Prescribed List.

1

 


 


 

  1. Other changes to the Prescribed List

 

3.1 The Committee supported a request from the Alcohol & Drugs Service to temporarily relax requirements for prescriptions for acamprosate and nalmefene to be validated by them before dispensing. The purpose of the validation is to confirm that these products, which are used in the treatment of alcohol mis-use, are only dispensed for those patients also receiving psycho-social support. However, this validation process has not been possible during the COVID pandemic and, prior to that, had been increasingly difficult to manage.  The process is under review and an alternative approach will be submitted to the next meeting of PBAC.

 

  1. Other considerations

 

Applications for the following products were considered by the Committee but not supported.

 

4.1  Hyaluronic acid injection (e.g. Ostenil Plus, Durolane) – these products, used in the management of pain and restricted mobility in degenerative and traumatic changes of the knee joint and other synovial joints, are classed as medical devices and do not require prescription. The request was for them to be prescribed by a limited number of practitioners in primary care. After careful consideration, the Committee did not recommend their inclusion in the Prescribed List but suggested that access to the products should be considered as part of the pathway of care for patients with musculoskeletal conditions.

 

4.2 Colecalciferol (vitamin D) capsules 400 Units, 800units – the Committee noted that recently published recommendations from NICE that colecalciferol is not recommended in the treatment or prevention of COVID-19 infection. However, low dose colecalciferol (400units daily) remains helpful for bone health in the general population. Since low dose colecalciferol can be bought from pharmacies, the Committee did not see a need to add it to the Prescribed List.

Our sites
Back to top
rating button